Gemtesa Drug Interactions: What to Avoid and What to Tell Your Doctor

One of Gemtesa's (vibegron) most often-cited advantages over other overactive bladder medications is its low risk of drug-drug interactions. That said, interactions do exist — and there are medications and health conditions you should discuss with your doctor before starting Gemtesa.

Why Gemtesa Has Fewer Drug Interactions Than Mirabegron

Many medications are metabolized (broken down) by a family of liver enzymes called cytochrome P450 (CYP) enzymes. If a drug inhibits or induces these enzymes, it can change how much of another drug is in your system — leading to drug interactions.

Mirabegron (Myrbetriq), the other beta-3 agonist for OAB, is a significant inhibitor of CYP2D6 — an enzyme that metabolizes about 25% of commonly used drugs. This creates interaction potential with antidepressants (SSRIs, TCAs), antipsychotics, opioids, beta-blockers, and tamoxifen.

Vibegron does NOT inhibit or induce CYP2D6, CYP3A4, or other major cytochrome P450 enzymes. It is a substrate of CYP3A4 (meaning CYP3A4 helps break it down), but it doesn't meaningfully affect other drugs metabolized by these enzymes. This makes Gemtesa a safer choice for patients on complex medication regimens.

The Most Important Interaction: Digoxin

The only clinically significant drug interaction identified for Gemtesa is with digoxin — a heart medication used for heart failure and certain arrhythmias (atrial fibrillation).

When Gemtesa is taken with digoxin:

Digoxin's maximum blood concentration (Cmax) increases by approximately 21%

Digoxin's overall exposure (AUC) increases by approximately 11%

Digoxin has a narrow therapeutic window — meaning even small increases in blood levels can cause toxicity. Symptoms of digoxin toxicity include nausea, vomiting, visual disturbances (halos, yellow-green tinting), and dangerous heart rhythm abnormalities.

What your doctor should do: Monitor serum digoxin levels before starting Gemtesa and during treatment. Titrate the digoxin dose as needed. Continue monitoring after stopping Gemtesa as well, since levels will shift again.

Drug-Drug Interaction: Other OAB Medications (Anticholinergics)

Taking Gemtesa with anticholinergic/antimuscarinic OAB medications (such as oxybutynin, solifenacin, tolterodine, darifenacin, or fesoterodine) increases the risk of urinary retention. While some providers do combine treatments in refractory cases, this should be done under close medical supervision with monitoring for retention symptoms.

P-glycoprotein (P-gp) Substrate Status

Vibegron is a substrate of P-glycoprotein (P-gp) — a drug efflux transporter. However, in studies, vibegron did not inhibit P-gp or other drug transporters (BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2K) at clinically relevant concentrations. This means that drugs that inhibit P-gp (like some HIV medications or antifungals) could theoretically raise vibegron blood levels, but this interaction is not considered clinically significant at typical doses.

What to Tell Your Doctor Before Starting Gemtesa

Make sure your prescriber knows about all medications, supplements, and vitamins you take — especially:

Digoxin (Lanoxin) — requires monitoring if you take both

Any other OAB medications (anticholinergics) — increased urinary retention risk

CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) — these may increase vibegron blood levels since vibegron is a CYP3A4 substrate

Any medications for heart conditions, blood pressure, or arrhythmias

History of bladder outlet obstruction or urinary retention

Food and Supplement Interactions

No specific food or supplement interactions have been identified for Gemtesa. It can be taken with or without food without affecting its pharmacokinetics. There are no known grapefruit juice interactions. For more detail on side effects to watch for, see Gemtesa Side Effects: What to Expect.